| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
Departments of 1 Pathology and 2 Laboratory Medicine, University of California San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California
Requests for reprints: Thea D. Tlsty, Department of Pathology, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, 513 Parnassus Avenue, HSW 451, San Francisco, CA, 94143-0511. Phone: 415-502-6116; Fax: 415-502-6163. E-mail: ttlsty{at}itsa.ucsf.edu.
The immediate-early gene, cyclooxygenase-2 (COX-2), is induced in a variety of inflammatory and neoplastic processes and is believed to play an important role in tumorigenesis. In this study, we identify an important upstream regulatory pathway of COX-2 expression in variant human mammary epithelial cells (vHMEC), which has been shown to exhibit phenotypes important for malignancy. We find that the stress-activated kinase, p38, is phosphorylated and activated in vHMEC compared with HMEC and is responsible for the expression of COX-2 in vHMEC as cells grow in culture. Furthermore in this capacity, p38 acts to stabilize the COX-2 transcript rather than activate COX-2 transcription. Inhibition of p38 kinase, using a chemical inhibitor, down-regulates COX-2 and decreases cell survival. Examination of archived tissue from women with ductal carcinoma in situ reveals epithelial cells that not only overexpress COX-2 but also have an abundance of activated phospho-p38 in the nucleus and cytoplasm, mirroring the expression observed in vitro. These epithelial cells are found within premalignant lesions as well as in fields of morphologically normal tissue that surround the lesions. In contrast, low phospho-p38 staining was observed in the majority of normal tissue obtained from reduction mammoplasty. These data help define the regulation of COX-2 expression in early carcinogenesis and provide alternative candidates for targeted prevention of COX-2-induced phenotypes and breast cancer.
Key Words: COX-2 p38 human mammary epithelial cells ductal carcinoma in situ field effect
This article has been cited by other articles:
![]() |
M. A. Troester, M. H. Lee, M. Carter, C. Fan, D. W. Cowan, E. R. Perez, J. R. Pirone, C. M. Perou, D. J. Jerry, and S. S. Schneider Activation of Host Wound Responses in Breast Cancer Microenvironment Clin. Cancer Res., November 15, 2009; 15(22): 7020 - 7028. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Neil, K. M. Johnson, R. A. Nemenoff, and W. P. Schiemann Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-{beta} through a PGE2-dependent mechanisms Carcinogenesis, November 1, 2008; 29(11): 2227 - 2235. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Junttila, S.-P. Li, and J. Westermarck Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival FASEB J, April 1, 2008; 22(4): 954 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bradley, R. van der Meer, N. Roodi, H. Yan, M. B. Chandrasekharan, Z.-W. Sun, R. L. Mernaugh, and F. F. Parl Carcinogen-induced histone alteration in normal human mammary epithelial cells Carcinogenesis, October 1, 2007; 28(10): 2184 - 2192. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Angelo and R. Kurzrock Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators Clin. Cancer Res., May 15, 2007; 13(10): 2825 - 2830. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Ostrander, A. R. Daniel, K. Lofgren, C. G. Kleer, and C. A. Lange Breast Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Heregulin-Induced Activation of ERK5 and p38 MAP Kinases in Breast Cancer Cells Cancer Res., May 1, 2007; 67(9): 4199 - 4209. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Reynolds, M. Sigaroudinia, G. Zardo, M. B. Wilson, G. M. Benton, C. J. Miller, C. Hong, J. Fridlyand, J. F. Costello, and T. D. Tlsty Tumor Suppressor p16INK4A Regulates Polycomb-mediated DNA Hypermethylation in Human Mammary Epithelial Cells J. Biol. Chem., August 25, 2006; 281(34): 24790 - 24802. [Abstract] [Full Text] [PDF] |
||||
![]() |
K J Schmitz, R Callies, J Wohlschlaeger, R Kimmig, F Otterbach, J Bohr, H-S Lee, A Takeda, K W Schmid, and H A Baba Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways J. Clin. Pathol., July 1, 2006; 59(7): 685 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ding, C. Erdmann, A. M. Chinnaiyan, S. D. Merajver, and C. G. Kleer Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues. Cancer Res., April 15, 2006; 66(8): 4095 - 4099. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |